Professor Benjamin Weinberg <\/b>(Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase II study where dostarlimab, an anti PD-1 monoclonal antibody, was administered to patients with MicroSatellite Instability-High (MSI-H) localized rectal cancer. Professor Weinberg discusses the excitement around the outcome of this phase II study (0:52). The DYNAMIC study aimed to assess if a circulating tumour DNA (ctDNA)-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk. Professor Weinberg discusses the findings of the DYNAMIC trial and the key takeaways (03:52).<\/p>\n
The abstracts entitled ‘Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer’ (Abstract number LBA5<\/a>) and \u2018Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial\u2019 (Abstract number LBA100<\/a>) were presented at the ASCO<\/a>\u00a0annual meeting,\u00a0June 3-7, 2022.<\/p>\n Disclosures<\/strong>: Benjamin Weinberg has received grant\/research support from Ipsen, is on the advisory board for Bayer and Taiho and the speaker’s bureau for AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Sirtex and Taiho.<\/p>\n Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.<\/p>\n